Leukemic cells exert immunosuppressive effects that interfere with dendritic cell (DC) function and hamper effective antileukemic immune responses. Here, we sought to enhance the immunogenicity of leukemic cells by loading them with the double-stranded (ds) RNA Toll-like receptor 3 (TLR3) ligand polyriboinosinic polyribocytidylic acid (poly(I:C)), mimicking viral infection of the tumor cells. Given the responsiveness of DC to TLR ligands, we hypothesized that the uptake of poly(I:C)-loaded leukemic cells by immature DC (iDC) would lead to DC activation. Primary acute myeloid leukemia (AML) cells and AML cell lines markedly responded to poly(I:C) electroporation by apoptosis, upregulation of TLR3 expression, enhanced expression of major histocompatibility complex (MHC) and costimulatory molecules and by production of type I interferons (IFN). Upon phagocytosis of poly(I:C)-electroporated AML cells, DC maturation and activation were induced as judged by an increased expression of MHC and costimulatory molecules, production of proinflammatory cytokines and an increase of T helper 1 (T H 1)-polarizing capacity. These immune effects were suboptimal when AML cells were passively pulsed with poly(I:C), indicating the superiority of poly(I:C) transfection over pulsing. Our results demonstrate that poly(I:C) electroporation is a promising strategy to increase the immunogenicity of AML cells and to convert iDC into activated mature DC following the phagocytosis of AML cells.
Introduction
Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults with the lowest survival rate of all leukemias. 1 For untreated AML patients, the median survival period is 3 months. With standard treatments for patients with de novo AML a high rate of first remission is achieved, but approximately 75% of patients in first remission relapse within 2 years. Current therapies are also associated with significant morbidity and mortality, particularly for patients older than 60 years. Therefore, novel treatment options are urgently needed, especially to prevent relapse. In an attempt to specifically target leukemic cells, therapeutic AML vaccines based on modified AML cells are currently under active investigation. [2] [3] [4] [5] The poor immunogenicity of AML cells represents a major hurdle for immunotherapy. 6 Strategies to enhance this immunogenicity include gene transfer in AML cells to increase the expression of costimulatory molecules and the secretion of proinflammatory cytokines. 4, 5, 7, 8 Recent insights in the field of tumor vaccination underscore the importance of activation of the innate immune system for induction of effective adaptive immunity, in which dendritic cells (DC) play a pivotal role as master regulators of the immune system. 9 DC acquire antigens from the micro-environment and it is believed that the outcome of antigen presentation to T cells, stimulation or tolerance, will be determined by the presence or absence of innate 'danger' signals that alarm DC. 10 In this view, pathogen-derived 'danger' signals, also called pathogen-associated molecular patterns, are recognized by pattern recognition receptors (PRR) present on DC. Activation of PRR results in DC maturation and activation, thereby creating an inflammatory milieu in which the antigens are captured and presented in a stimulatory fashion to T cells. 11, 12 Toll-like receptors (TLR) 1-10 are well-studied examples of such PRR and their effect following triggering by (synthetic) TLR ligands has been well documented. 13, 14 Double-stranded RNA (dsRNA), a major viral signature, is known to be a ligand for TLR3, localized in endosomal vesicles, as well as for cytoplasmic dsRNA receptors such as melanoma differentiation antigen-5 (mda-5), protein kinase regulated by RNA (PKR) and retinoic acid-inducible gene-I (RIG-I). Triggering of these receptors leads to NF-kB activation and production of type I interferon (IFN) that have various antiviral and immunostimulatory activities. [15] [16] [17] In this context, several studies have shown that dsRNA can have immunostimulatory effects when it is transfected into DC or tumor cells. Diebold et al. 18 showed that murine non-plasmacytoid DC secrete high levels of IFN-a in response to dsRNA, only when the latter was introduced into the cytoplasm to mimic direct viral infection. For human DC, Michiels et al. 19 reported that higher numbers of Melan-A-specific cytotoxic T lymphocytes (CTL) were obtained following stimulation with Melan-A mRNA-loaded DC that were co-electroporated with poly(I:C 12 U), a clinical-grade dsRNA analog, as compared to DC matured by an inflammatory cytokine cocktail. In vivo mouse studies have shown that vaccination with dsRNAelectroporated tumor cells enhances the antitumor activity via TLR3 activation in the endosomes of mouse DC, resulting in a protective antitumor response mediated by cell-associated but not by soluble dsRNA. 20, 21 To date, however, little is known on the responsiveness of AML cells to dsRNA treatment and the effect of dsRNA-loaded tumor cells on human DC. Here we mimicked viral infection of AML cells by electroporating or pulsing primary AML cells and AML cell lines with poly(I:C), a synthetic dsRNA analog. We demonstrate that poly(I:C) electroporation of AML cells, as opposed to poly(I:C) pulsing, leads to increased apoptosis, enhanced TLR3 expression, upregulation of major histocompatibility complex (MHC) and costimulatory molecules expression and proinflammatory cytokine production. We also show that the uptake of poly(I:C)-loaded AML cells by human DC results in effective DC activation and maturation and in an increase of their T H 1-polarizing capacity.
Materials and methods

Source of primary cells and cell lines
Peripheral blood from healthy donors was obtained from buffy coats provided by the Antwerp Blood Transfusion Center. Peripheral blood and bone marrow samples from six newly diagnosed patients with AML (Supplementary Table 1) were collected after obtaining informed consent. Only patients with 475% CD33 þ or CD34 þ leukemic cells in blood or bone marrow were included in this study. Peripheral blood mononuclear cells (PBMC) and bone marrow mononuclear cells were isolated by Ficoll-Hypaque gradient separation (LSM; MP Biomedicals, Asse-Relegem, Belgium). The human myeloid leukemia cell lines NB-4 and U-937 were obtained from the Deutsche Sammlung von Mikroorganismen und Zellkulturen (Braunschweig, Germany) and the American Type Culture Collection (Rockville, MD, USA), respectively. Cells were cultured in complete medium consisting of Iscove's modified Dulbecco's medium (IMDM; Cambrex Bio Science, Verviers, Belgium) supplemented with L-glutamine (584 mg/l), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES, 25 mM), gentamicin (10 mg/l; Invitrogen, Merelbeke, Belgium), amphotericin B (1 mg/l Fungizone; Invitrogen) and 10% fetal calf serum (FCS; Perbio Science, Erembodegem, Belgium). Cells were maintained in logarithmic phase growth at 371C in a humidified atmosphere supplemented with 5% CO 2 . In some experiments, AML cells were irradiated at a dose of 60 Gy, resulting in o5% viable cells 24 h after irradiation.
In vitro generation of human monocyte-derived DC
Starting from PBMC, monocytes were isolated using CD14 microbeads according to manufacturer's protocol (Miltenyi Biotec, Amsterdam, The Netherlands). Purity after isolation was 490%. After isolation, CD14 þ cells were plated in sixwell plates (Corning Life Sciences, Schiphol-Rijk, The Netherlands) at a concentration of 0.5 Â 10 6 cells per ml in IMDM supplemented with 2.5% human AB (hAB) serum (MP Biomedicals). Sixty ng/ml granulocyte-macrophage colony-stimulating factor (GM-CSF; Leucomax, Novartis Pharma, Basel, Switzerland) and 25 ng/ml interleukin (IL)-4 (Biosource, Nivelles, Belgium) were added to the cultures at day 0. Immature DC were harvested on day 5.
Treatment of cells with poly(I:C) or IFN type I or II
Electroporation of poly(I:C) (Invivogen, Paris, France) was performed as described previously 22 for electroporation of mRNA with minor modifications. Briefly, leukemic cells were washed twice and resuspended to a final concentration of 25-50 Â 10 6 cells per ml. Subsequently, 0.2 ml of the cell suspension was mixed with 20 mg of poly(I:C) (unless stated otherwise) and electroporated in a 0.4 cm cuvette at 300 V and 150 mF using an Easyject Plus device (EquiBio, Ashford, UK). Immediately after electroporation, cells were washed extensively to remove the excess of poly(I:C). Pulsing of cells with poly(I:C) was performed by adding the indicated amounts directly to the culture medium during 18 h and cells were extensively washed before coculture with iDC. Interferon-a (Peprotech, Rocky Hill, NJ, USA) or IFN-g (Biosource) were added for 24 h to NB-4 or U-937 cells at a concentration of 1250 and 1000 U/ml, respectively. To block cytokine secretion, the protein transport inhibitor brefeldin A (Golgi Plug; BD) was added.
Flow cytometry
Apoptosis was measured by staining with annexin V (FITCconjugated; Becton Dickinson (BD), Erembodegem, Belgium) and ethidium bromide (Sigma, Bornem, Belgium) to distinguish between apoptotic and necrotic cells. Staining of B7 and MHC molecules on AML cells and DC was performed using FITC-or PE-labeled monoclonal antibodies for CD80, CD86, HLA-ABC and HLA-DR (BD). Ethidium bromide was used to include only viable cells in the analysis. Three-color flow cytometry was performed on a FACScan (BD). Relevant fluorochrome-labeled isotype-matched antibodies were used as negative controls in all experiments. Usually, 10 000 events per sample were analyzed using CellQuest software (BD).
Coculture of DC and tumor cells
After washing, poly(I:C)-treated and untreated tumor cells were cocultured with iDC in IMDM with 2.5% hAB serum at a ratio 1:1. Twenty-four hours later, phagocytosis, expression of maturation markers and viability were measured by flow cytometry after staining DC with anti-DC-SIGN monoclonal antibodies (FITC-or PE-conjugated; BD). Leukemic cells were DC-SIGN-negative. Supernatant was collected after 24 h for IL-6, tumor necrosis factor (TNF)-a, IFN-a and IFN-b enzymelinked immunosorbent assay (ELISA; Endogen, Woburn, MA, USA). For determining the phagocytosis capacity of iDC, 10 Â 10 6 leukemic cells per ml phosphate-buffered saline were stained with carboxy fluorescein diacetate succinimide ester (CFSE; Invitrogen) at a concentration of 2 mg CFSE per ml for 5 min at room temperature. Thereafter, FCS was added to block the staining reaction and cells were washed to remove the excess of CFSE. Stained leukemic cells were allowed to rest for 24 h before coculture with iDC. Flow cytometric cell detection was performed using an Epics XL-MCL (Beckman Coulter, Mijdrecht, The Netherlands) flow cytometer. Cell aggregates having a larger forward scatter-width (FSC-W) compared with single cells were gated out using a dot plot showing FSC-area (FSC-A) versus FSC-W.
Priming of naïve T cells
DC were cocultured with irradiated AML cells at a ratio 1:1. After 24 h all produced cytokines were washed away and DC were plated with allogeneic naïve T cells in 24-well plates at a ratio 1:10. Naïve CD4 þ CD45RA þ T cells were isolated from PBMC using the naïve CD4 þ T cell enrichment kit, according to the protocol (Easysep, StemCellTechnologies, Grenoble, France). After 5 days, IL-2 (30 U/ml; Biosource) was added and at day 10, T cells were restimulated for 5 h with phorbol 12-myristate 13-acetate (PMA; 50 ng/ml; Sigma) and ionomycin (1 mg/ml; Sigma). Brefeldin A was added to block cytokine secretion. After restimulation, cells were fixed and permeabilised using FACS Lysing Solution and Permeabilizing Solution 2 (BD) before blocking with mouse gamma globulins (Jackson ImmunoResearch Laboratories, De Pinte, Belgium) and staining with FITC-labeled and PE-labeled monoclonal antibodies (Pharmingen, Erembodegem, Belgium) specific for IFN-g and IL-4, respectively.
Real time quantitative reverse transcriptase-polymerase chain reaction (real time RT-PCR)
Total RNA was isolated from 1-5.10 6 cells using an RNeasy kit (Qiagen, Antwerp, Belgium). DNase treatment was performed during the RNA isolation according to manufacturer's protocol. cDNA was obtained by incubating 1-3 mg total RNA with 1 mM dNTP, 0.2 mg random hexamer primers, 20 units of RNasin and 40 units of Moloney murine leukemia virus reverse transcriptase in a total volume of 20 ml for 10 min at 251C, 1 h at 421C and 10 min at 701C according to manufacturer's protocol (Fermentas, St-Leon Rot, Germany).
Quantitative PCR was performed in an I-Cycler (Biorad, Nazareth, Belgium). One microliter of cDNA was added to a PCR mixture containing 12.5 ml of iQ-SyBR Green Supermix (Biorad) and 0.8 mM of each sense and antisense primers (Invitrogen) in a total volume of 25 ml. After an initial denaturation step at 951C for 3 min, amplifications consisted of 50 cycles of denaturation at 941C for 30 s, annealing for 30 s at 551C and extension at 721C for 1 min. Primer pairs used were specific for human TLR3 (forward 5 0 -ATTGGGTCTGGGAA CATTTCTCTTC-3 0 ; reverse 5 0 -GTGAGATTTAAACATTCCTCTT CGC-3 0 ; amplicon: 319 bp) 23 and ABL1 (forward 5 0 -AGCA TCTGACTTTGAGCC-3 0 ; reverse 5 0 -CCCATTGTGATTATAGCC TAAGAC-3 0 ; amplicon: 194 bp). The primer pair for TLR3 spans an intron region in the genomic (g)DNA to control for contamination with gDNA. RT-PCR products were analyzed in a 2% agarose gel stained with 0.5 mg/ml ethidium bromide and visualized by UV light.
Statistical analysis
Quantitative experiments were analyzed using Student's t-test. All P-values were obtained by two-tailed tests and differences were considered statistically significant when Po0.05.
Results
Apoptosis and increased expression of B7 and MHC molecules on acute leukemic cells after poly(I:C) electroporation
The presence of intracellular dsRNA has been shown to induce apoptosis, for example in virally infected cells. [24] [25] [26] Therefore, we checked apoptosis in NB-4 cells 24 h after poly(I:C) electroporation or passive pulsing. Indeed, we could demonstrate an increase of late apoptotic cells (binding annexin V and positive for ethidium bromide) from 1679% for non-or mocktreated control NB-4 cells to 29710, 44710 and 5673% for NB-4 cells electroporated with 4, 20 and 100 mg poly(I:C) respectively (Figure 1a) . Pulsing of leukemic cells with poly(I:C) did not lead to a similar increase in apoptosis (Figure 1a) . Apoptosis induced by poly(I:C) electroporation (20 mg) of primary leukemic cells was subject to donor variability, with a mean increase of 875% annexin V-binding cells 24 h after electroporation between mock-electroporated and poly(I:C)-electroporated leukemic cells. Given the potential of AML cells to differentiate in vitro into leukemic DC-like cells, [27] [28] [29] we also investigated the effect of poly(I:C) on the membrane expression of B7 and MHC molecules by staining with monoclonal antibodies specific for CD80, CD86, MHC class I and class II. Poly(I:C) transfection of NB-4 (Figure 1b) , U-937 and primary leukemic cells led to slightly upregulated levels of CD80, CD86 and MHC molecules on viable cells, to the same extent as IFN-g treatment of the cells (Figure 1b) , in contrast to pulsing with poly(I:C) (data not shown). Further increase of the concentration of poly(I:C) used for electroporation did not result in increased expression of CD80 and CD86 (data not shown). Notably, the combination of IFN-g treatment and poly(I:C) electroporation further increased the upregulation of B7 and MHC molecules to levels higher than either alone (Figure 1b) . Based on these results, we conclude that electroporation, but not pulsing, of myeloid leukemic cells with poly(I:C) results in increased levels of apoptosis and increased expression of costimulatory and MHC molecules.
Proinflammatory cytokine secretion by AML cells treated with poly(I:C)
The secretion of the proinflammatory cytokines TNF-a and IFN-a was detected in the supernatant 24 h after the treatment of leukemic cells with poly(I:C). TNF-a production increased in primary leukemic cells from four of six AML patients after electroporation but not after pulsing of poly(I:C) ( Table 1) . However, TNF-a production was not observed in AML cell lines after poly(I:C) electroporation. Strikingly, electroporation with poly(I:C) resulted in marked IFN-a production in both myeloid cell lines and all AML patient samples tested (Table 1) . Only two AML patients (P2 and P4) produced a relatively low amount of IFN-a in response to poly(I:C) pulsing. For IFN-b, similar results were observed as for IFN-a (data not shown). Our results clearly show that poly(I:C) electroporation of AML cells leads to inflammatory cytokine production by myeloid leukemic cells, superior to cytokine production after pulsing with poly(I:C).
TLR3 expression in leukemic cells and upregulation after treatment with poly(I:C)
Because poly(I:C) is a ligand for TLR3, we checked the expression of TLR3 before and after pulsing or electroporation with poly(I:C). Using real time quantitative RT-PCR with primers specific for TLR3, mRNA encoding TLR3 could be detected in all AML cell lines and patient samples tested (Supplementary  Table 2 ; mean7s.d.: 10.08716.09; range: 0.09-48.00 TLR3 copies per 1000 copies of ABL1). Electroporation with 20 mg poly(I:C) as well as passive pulsing of leukemic cells from AML patients with 100 mg/ml poly(I:C) led to a significant increase in mRNA encoding TLR3 (range 10-61-fold increase for electroporation, P ¼ 0.017 and 4-25-fold increase for pulsing, P ¼ 0.037). Interestingly, the increase in TLR3 mRNA copies after electroporation with poly(I:C) was significantly higher (P ¼ 0.015, paired Student's t-test) than after passive pulsing with poly(I:C), although fivefold higher amounts of poly(I:C) were used for pulsing. To further investigate the role of the produced type I IFN in the observed TLR3 upregulation, we checked TLR3 expression after adding IFN-a to NB-4 ( Figure 1c 
DC maturation and activation after the uptake of poly(I:C)-electroporated AML cells
Given the effects of intracellular dsRNA on AML cells as described above, we wanted to assess the potential of poly(I:C)-loaded AML cells to activate DC after uptake. Flow cytometric analysis of the expression of costimulatory and MHC molecules on the DC membrane revealed a marked increase in the expression of CD80, CD86 and MHC molecules after the uptake of irradiated poly(I:C)-electroporated NB-4 cells, in contrast to DC that phagocytosed unmodified or mock-electroporated NB-4 cells (Figure 2b ). Further increase of the concentration of poly(I:C) used for electroporation of NB-4 cells (2-50 mg) did not result in increased expression of CD80 and CD86 on DC (data not shown). DC that phagocytosed poly(I:C)-pulsed NB-4 cells exhibited a similar increase in MHC molecules, but a lower increase in CD80 and CD86 expression (Figure 2b) . The same increase in costimulatory and MHC molecules was seen after coculture of DC with non-irradiated poly(I:C)-loaded primary AML cells or AML cell lines (data not shown). Next to upregulation of maturation markers, we detected the production of TNF-a and IL-6 in the supernatant from cocultures of iDC and poly(I:C)-electroporated as well as poly(I:C)-pulsed NB-4 cells. The amount of TNF-a increased when NB-4 cells were electroporated with increasing amounts of poly(I:C) (Figure 2c ). For cocultures of DC with poly(I:C)-electroporated primary AML cells or AML cell lines, TNF-a production ranged from 200 to 1880 pg/ml and IL-6 production from 52 to 1163 pg/ml (n ¼ 6). Cocultures of DC with irradiated NB-4 cells resulted in TNF-a production ranging from 689 to 1909 pg/ml and IL-6 production from 370 to 1107 pg/ml (n ¼ 3). Notably, substantial amounts of IFN-a were detected only in cocultures of DC with dsRNAelectroporated but not dsRNA-pulsed AML cells, ranging from 408 to 17315 pg/ml (n ¼ 8) (Figure 2c , Not irradiated). Supplementary irradiation of AML cells resulted in lower but still significant levels of IFN-a (Figure 2c, Irradiated) for the dsRNA electroporation condition. Similar results were obtained for IFN-b (data not shown). IL-12p70 production by DC was absent or low, ranging from 0 to 47 pg/ml for DC cocultured with poly(I:C)-electroporated (20 mg) NB-4 cells (13719 pg/ml; n ¼ 7). Using 100 mg for poly(I:C) electroporation, IL-12p70 ranged from 0 to 605 pg/ml (1897220 pg/ml, n ¼ 7). In conclusion, we observed that the uptake of dsRNA-electroporated AML cells by iDC leads to upregulation of maturation markers on DC and to production of TNF-a, IL-6 and type I IFN.
T H 1-polarizing capacity of DC after the uptake of poly(I:C)-loaded AML cells
To evaluate the effect of poly(I:C)-loaded AML cells on the T H 1-polarizing capacity of DC, DC were cocultured for 24 h with irradiated primary AML or NB-4 cells. Then, DC cultures were tested for their capacity to prime allogeneic naïve CD4 þ CD45RA þ T cells. Using intracellular cytokine staining, we observed a significant increase in T H 1-cells (IFN-g-positive CD4 þ T cells) when DC had taken up poly(I:C)-electroporated primary AML cells or AML cell lines as compared to mockelectroporated primary AML cells or AML cell lines (Figure 3a and b; Po0.05). This increase in T H 1-polarizing capacity was almost absent for DC that phagocytosed NB-4 cells passively Table 1 Cytokine production after treatment with poly(I:C) pulsed with poly(I:C), with or without mock electroporation of NB-4 cells after pulsing (Figure 3a) . Our data show that DC, following the uptake of poly(I:C)-electroporated AML cells, acquire the ability to prime a T H 1 response.
Discussion
In this study, we assessed the immunological responsiveness of primary AML cells and AML cell lines to dsRNA. We also Poly(I:C) electroporation of AML cells, in contrast to pulsing with poly(I:C), led to a marked increase in apoptosis, expression of MHC and costimulatory molecules and production of the proinflammatory cytokines TNF-a and type I IFN. These findings could be explained by activation of the key transcription factors NF-kB and interferon regulatory factor 3 (IRF3), known to be common endpoints in the signaling cascades of several dsRNA receptors. [15] [16] [17] In spite of the shared endpoints, the outcome of dsRNA treatment is dependent on cell type 15, 30 and the method of exposure. 18, 19, 21, 31 Indeed, in our study, we demonstrate that it is necessary to transfect dsRNA into the cytoplasm of AML cells in order to exert its immunostimulatory effects. These data corroborate the previously published data on dsRNA treatment of thyrocytes or murine non-plasmacytoid DC. Incubation of Fisher rat thyroid cell line-5 (FRTL-5) or human thyrocytes with poly(I:C) did not result in increased MHC class I expression and TLR3 mRNA, in contrast to poly(I:C) transfection. 31 Nonplasmacytoid murine DC made only background levels of IFN-a following poly(I:C) pulsing, in contrast to the high levels of IFN-a production when poly(I:C) was delivered intracellularly by transfection. 18 Interestingly, we could not detect IFN-a production in supernatants of poly(I:C)-electroporated primary or established lymphoid leukemic cells, nor in supernatants of poly(I:C)-electroporated epithelial cell lines (data not shown), suggesting that IFN-a production by poly(I:C) electroporation might be limited to cells of myeloid origin.
We are the first to demonstrate basal TLR3 expression in primary AML cells. In spite of the observed TLR3 upregulation following dsRNA transfection, it is likely that the effects observed in AML cells were more dependent on activation of cytosolic dsRNA receptors (mda-5, RIG-I, PKR) than on endosomal TLR3 activation. 18, 32 The enhancement of TLR3 expression in AML cells by incubation with type I IFN was consistent with previous observations using other cell types. 31, [33] [34] [35] [36] The addition of brefeldin A to dsRNA-electroporated AML cells blocked the secretion of type I IFN, but did not completely block the increase in TLR3 expression. These results suggest that type I IFN are involved to some extent in the observed TLR3 upregulation after poly(I:C) transfection, as also found by Harii et al. 31 for dsRNA-electroporated thyrocytes. In accordance with a recent report on murine CD8a þ DC activation by dsRNA-loaded tumor cells, 20 this is the first report showing human DC activation following the incubation of DC with dsRNA-loaded AML cells. These activated DC exhibited the elevated levels of MHC and costimulatory molecules, as well as the production of TNF-a, IL-6 and type I IFN. Strikingly, IFN-a production was exclusively found when DC were activated by dsRNA-electroporated AML cells, while TNF-a was also present in DC cultures with dsRNA-pulsed AML cells. Noteworthy, all the effects described for electroporated cells resulted from a very brief exposure to a low amount of poly(I:C) (20 mg) during the electroporation process (72 min), while dsRNA-pulsed cells were exposed to higher concentrations (100 mg/ml) overnight. The superiority of electroporation over pulsing became clear when analyzing the T H 1-polarizing capacity of DC: only DC that had taken up dsRNA-electroporated AML cells had a significant increase in T H 1-polarizing capacity.
Because the percentage of apoptotic AML cells increased after poly(I:C) electroporation, the observed DC activation could have been due to an increased uptake of apoptotic cells. Therefore, irradiation of the AML cells was performed to rule out this possibility. Although irradiated AML cells were phagocytosed more efficiently than non-irradiated cells, no DC activation was observed following the phagocytosis of unmodified or mockelectroporated irradiated AML cells. These results are consistent with previously published data for AML cells and other tumor cells, showing that apoptotic cells do not induce DC maturation, 37, 38 unless innate danger signals such as TLR ligands 20, 39, 40 or inflammatory cytokines 41 are provided by the apoptotic tumor cells. Nevertheless, supplementary irradiation will be imperative for clinical use of dsRNA-loaded tumor cells for safety concerns. In our experiments, we did not observe a decrease in DC maturation and activation by irradiation of AML cells, except for a substantial decrease in IFN-a production. Currently, we are performing experiments to look at the cross-priming potential of human DC activated by the uptake of poly(I:C)-loaded tumor cells. In conclusion, we found that AML cells respond to dsRNA transfection by the upregulation of MHC and costimulatory molecules and by production of proinflammatory cytokines. Furthermore, poly(I:C)-electroporated AML cells have the ability to activate and mature human DC with enhancement of the T H 1-polarizing capacity of DC. These results provide a strong basis for future research on the potential of dsRNA-transfected AML cells as a vaccine for immunotherapy of leukemia.
